Under the theme 'Entering a New Era for Market Access', this year's Summit will explore the future of drug pricing from a balanced perspective. The rebate system, new powers for Medicare Part D, global factors that could affect the pricing and market access landscape in the US, as well as the effects of public pressure and President Trump's Blueprint to Lower Drug Prices. will all be examined under the chairmanship of Sarah Neville, Global Pharmaceuticals Editor of the Financial Times.
Standard Ticket Price: USD 900.0
Speakers: Sarah Emond, Executive Vice President and Chief Operating Officer Institute, for Clinical and Economic Review (ICER), Robert Dubois, Chief Science Officer and Executive Vice President, National Pharmaceutical Council (NPC), Rick R. Suarez, Senior Vice President, US Market Access, AstraZeneca, Tony Barrueta, Senior Vice President of Government Relations, Kaiser Foundation Health Plan and Hospitals, Kathleen Tregoning, Executive Vice President, External Affairs Sanofi, Christoph Glaetzer, Vice President, Global Market Access Janssen, Chris Leibman, Senior Vice President, Value and Access Biogen